Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to heart failure with a focus on LVEF ≥ 40%. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated April 20, 2026.

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 82    

Filtered results: 82

Sex Differences in Cardiovascular–Kidney–Metabolic Syndrome: The FINE-HEART Pooled Analysis

Pablon M., et al, EHJ. 2026

Pabon M, 12 03 2026

Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire

Hamatani Y., et al, EHJ. 2026

Hamatani Y, 11 03 2026

Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Foa A., et al, JACC-HF. 2026

Foa A, 10 03 2026

Clinical Risk Prediction Models for Worsening Heart Failure Events and All-Cause Mortality in Adults with Mild-to-Moderate Chronic Kidney Disease

Patel S., et al., ESC-HF. 2026

Patel S, 11 02 2026

Efficacy and Safety of the Kidney Function–Based Finerenone Dosing Strategy Used in FINEARTS-HF

Chimura M., et al, JACC. 2026

Chimura M, 10 02 2026

Established and Emerging Pharmacologic Options and Unmet Need in HFpEF and HFmrEF

Sauer A., et al., ESC-HF. 2026

Sauer A, 10 02 2026

Finerenone, Polypharmacy, and Clinical Outcomes in Heart Failure: Pre-Specified Analysis from the FINEARTS-HF Trial

Hamatani Y., et al., EJHF. 2026

Hamatani Y, 10 02 2026

A Bayesian Analysis of Finerenone in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: A Pre-Specified Analysis of FINEARTS-HF

Henderson A, et al, EHJ-CP. 2026

Henderson A, 09 02 2026

Finerenone and eGFR Slope across Different Levels of Baseline Albuminuria and eGFR: Insights from FINEARTS-HF

Mc Causland FR., et al, JASN. 2026

Mc Causland FR, 02 02 2026

Efficacy of Finerenone in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of Heart Rate and Heart Rhythm in the FINEARTS-HF Trial

Foa A., et al, JACC. 2026

Foa A, 31 12 2025